ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2017
Setting the stage for expanding HIV pre-exposure prophylaxis use in Canada.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- HIV testing among heterosexual Black men in Toronto: What are the determinants?Canadian journal of public health = Revue canadienne de sante publique · 2025Article
- Pre-exposure prophylaxis and bacterial sexually transmitted infections (STIs) among gay and bisexual men.Sexually transmitted infections · 2023Article
- Observational
- Examining provincial PrEP coverage and characterizing PrEP awareness and use among gay, bisexual and other men who have sex with men in Vancouver, Toronto and Montreal, 2017-2020.Journal of the International AIDS Society · 2022Article
- Online Sexual Health Information Seeking Patterns Differentiated by Social Location and Physical Location among Gay and Bisexual Men in Ontario, Canada.International journal of sexual health : official journal of the World Association for Sexual Health · 2022Article
- Transporting Subgroup Analyses of Randomized Controlled Trials for Planning Implementation of New Interventions.American journal of epidemiology · 2021Article
- Attitudes and Practices of a Sample of Nova Scotian Physicians for the Implementation of HIV Pre-Exposure Prophylaxis.HIV/AIDS (Auckland, N.Z.) · 2021Article
- Real-World Eligibility for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs.AIDS and behavior · 2020Article
- Cohort profile: l'Actuel Pre-Exposure Prophylaxis (PrEP) Cohort study in Montreal, Canada.BMJ open · 2019Article
- The role of public health units in the delivery of HIV pre-exposure prophylaxis (PrEP).Canadian journal of public health = Revue canadienne de sante publique · 2019Article
- Can we eliminate HIV?Canadian family physician Medecin de famille canadien · 2018Article
- Evolving Toward Shared HIV Care Using the Champlain BASE eConsult Service.MDM policy & practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human immunodeficiency virus (HIV) infection continues to disproportionately affect vulnerable populations in Canada; particularly men who have sex with men (MSM). Novel HIV prevention strategies have recently expanded from the use of non-occupational post-exposure prophylaxis (nPEP) after high risk exposures to the use of pre-exposure prophylaxis (PrEP) in which individuals reduce risk of HIV infection through use of combination antiretrovirals taken prior to risk exposure. With approval of tenofovir/emtricitabine (TDF/FTC) for use as PrEP only in early 2016, and with limited public funding to date, uptake in Canada is in its preliminary stages. These biomedical prevention strategies have proven efficacy for MSM, and they may have potential for other at-risk populations. With generic formulations of TDF/FTC now available in Canada, there is an opportunity for widespread implementation. Expanding knowledge of health care providers across Canada on how best to assess, refer for or prescribe and monitor PrEP will contribute to the current efforts to reach the global goal of eliminating new HIV infections.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.